|Bid||66.16 x 1100|
|Ask||66.17 x 900|
|Day's range||66.00 - 66.82|
|52-week range||45.76 - 68.34|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||N/A|
|Earnings date||04 Feb 2021|
|Forward dividend & yield||1.96 (2.95%)|
|Ex-dividend date||31 Dec 2020|
|1y target est||74.88|
U.S. FDA Accepts for Priority Review Application for Opdivo as Adjuvant Therapy for Patients w/Resected Esophageal or Gastroesophageal Junction Cancer
US FDA Accepts for Priority Review Application for Opdivo Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer....
Bristol-Myers Squibb (BMY) closed the most recent trading day at $66.54, moving +0.79% from the previous trading session.